Peptide therapy TikTok claims: what the science actually supports

What did @conciergemd actually say?

The creator responded to a viewer question about chronic headaches by suggesting several peptides as potential aids for underlying causes. They named DSIP for sleep-related headaches, BPC-157 and TB-500 for inflammation or gut issues, and semax and selank for stress and mood imbalances. Their framing was cautious: they said these peptides "might help some of the symptoms or the processes" rather than claiming a cure. That hedging matters, and it's worth noting before we dig into the actual science.

They also correctly identified that chronic headaches are rarely one-cause problems. Hormones, sleep dysfunction, gut health, and stress are all legitimate areas of investigation in headache medicine. That multi-system framing is not wrong. The problem is in the leap from "these systems matter" to "here are specific peptides for each one."

Does the science back this up?

For most of these peptides, the honest answer is: not yet, at least not in humans with chronic headaches. The evidence base is thin, animal-heavy, and nowhere near the level needed to recommend specific peptides for a specific symptom cluster.

DSIP (delta sleep-inducing peptide) has been studied since the 1970s. Some early research suggested it could alter sleep architecture, but replication has been inconsistent. Monnier et al. (1977, European Journal of Biochemistry) described its original isolation, but controlled human trials showing reliable sleep improvement are lacking. BPC-157 has a more active research profile. Sikiric et al. (2018, Current Neuropharmacology) reviewed its anti-inflammatory and gut-protective effects in animal models, but no randomized controlled trials in humans with headache exist. TB-500 (a synthetic version of thymosin beta-4) has shown tissue repair properties in animal studies, but again, human headache data is nonexistent. Semax and selank have the most neurological relevance here. Semax has been studied in Russia for cognitive function and neuroprotection. Dolotov et al. (2006, Journal of Neurochemistry) showed it modulates BDNF in rodents. Selank has anxiolytic properties documented in some small Russian trials. Neither has been tested in chronic headache populations in rigorous Western trials.

What did they get wrong (or right)?

They got the framing mostly right by not overclaiming. Saying a peptide "might help" is meaningfully different from saying it treats headaches. Credit where it's due.

What they got wrong, or at minimum glossed over, is the gap between mechanism and outcome. A peptide improving sleep in a rodent model does not mean it will reduce your chronic migraines. The creator presents a tidy cause-and-effect map: inflammation causes headaches, BPC-157 reduces inflammation, therefore BPC-157 helps headaches. That logic chain skips several critical steps, including bioavailability in humans, dosing variables, route of administration, and whether the peptide even reaches relevant tissues in meaningful concentrations.

The "semaxilank" phrasing, which appears to mean semax and selank used together, is presented casually as something the creator likes as a combo. Stacking peptides with overlapping neurological activity without clinical trial data is not something a fact-checker can endorse. The combination may be fine. It may not be. We do not know.

What should you actually know?

Chronic headaches affect roughly 4 percent of the global population daily, according to the Global Burden of Disease Study (GBD 2016, The Lancet Neurology). The standard of care involves evidence-based interventions: preventive medications like topiramate and propranolol, CGRP antagonists for migraines, behavioral interventions, and sleep hygiene. These have clinical trial data behind them.

Peptide therapy for headaches sits outside that evidence base right now. That does not make it useless. It means the risk-benefit calculation cannot be done with precision. If you are considering peptides for chronic headaches, the questions to ask a provider are: What is the specific mechanism you are targeting in my case? What is the route of administration and why? What monitoring will happen? And critically: what happens if it does not work?

Telehealth platforms offering peptide therapy should be ordering labs, taking thorough histories, and not building treatment plans from TikTok logic chains. The creator here is not doing obvious harm, but the confidence of the framing outpaces the evidence, and patients with chronic pain deserve to know that.